CDD for Alto Capital’s investment in Diatech Pharmacogenetics

The Alto Capital IV fund, managed by Alto Partners has completed the acquisition of 40% of Diatech Pharmacogenetics.

Diatech, founded in 1998 by Fabio Biondi and headquartered in Jesi (Ancona, Marche), is a leading provider of diagnostic solutions and reagents in the pharmacogenetics and pharmacogenomics sectors. The company provides customized genomic testing solutions in the oncological disease niche, aimed at optimizing cancer treatment effectiveness through increased diagnosis precision. Diatech Group enjoys today a leading position in the Italian market for genetic tests in the oncology field (approx. 70% market share).

PMSI provided CDD, analysing Diatech’s market position, size and competitor dynamics, focusing on PCR and NGS technologies.